FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3024885593> ?p ?o ?g. }

• W3024885593 endingPage "728" @default.
• W3024885593 startingPage "724" @default.
• W3024885593 abstract "Objective: To explore the predictive value of minimal residual disease (MRD) level in Ph-negative precursor B-acute lymphoblastic leukemia (ALL) patients. Methods:De novo 193 Ph-negative B-ALL patients from Sep 2010 to Nov 2017 were involved in the study. The patients' MRD evaluation which can be performed by multiparametric flow cytometry (MFC) after 1 month, 3-month, 6-month treatment. Relapse free survival (RFS) and overall survival (OS) were compared in patients with different MRD level. Results: The median follow-up was 22 months. All patients was evaluated at 497 MRD level. Patients who reach the good MRD level at 1 month (<0.1% or ≥0.1%), 3-month (negative or positive), 6-month (negative or positive) had a significantly higher probability of estimated RFS (74.5% vs 29.9%; 75.6% vs 29.7%; 74.6% vs 11.6%) and of estimated OS (67.5% vs 30.3%; 71.6% vs 27.8%; 74.0% vs 15.7%). Patients who reach the MRD negative at all 3 times had a significantly higher probability of estimated RFS (80.5% vs 30.5%) and better estimated OS (77.1% vs 29.4%) compared to patients with at least MRD failure in one time (P<0.001). Multivariable analysis showed MRD level at 3-month was an independent prognostic factor for DFS and OS. Conclusion: MRD is an important prognosis factor for Ph-negative B- ALL patients.目的： 探讨微小残留病（MRD）水平在Ph染色体阴性的急性B淋巴细胞白血病（Ph(-) B-ALL）中的预后意义。 方法： 采用多色流式细胞术对2010年9月至2017年11月初诊的193例Ph(-) B-ALL患者在治疗后1、3、6个月进行骨髓MRD监测，并对不同MRD水平患者的预后进行比较。 结果： 中位随访22（1~92）个月，所有193例患者共行497次MRD检测。1个月时MRD水平<0.1%和≥0.1%患者的3年预期无复发生存（RFS）率分别为74.5%和29.9%，3年预期总生存（OS）率分别为67.5%和30.3%；3个月时MRD水平阴性和阳性患者的3年预期RFS率分别为75.6%和29.7%，3年预期OS率分别为71.6%和27.8%；6个月时MRD水平阴性或阳性患者的3年预期RFS率分别为74.6%和11.6%，3年预期OS率分别为74.0%和15.7%，差异均有统计学意义（P值均<0.001）。3个监测点全部达到MRD阴性标准的患者与至少1次未达到MRD阴性标准的患者比较，3年预期RFS、OS率差异均有统计学意义（80.5%对30.5%，77.1%对29.4%，P值均<0.001）。多因素分析结果显示，3个月时的MRD水平是Ph(-) B-ALL患者独立的预后因素之一。 结论： 治疗后MRD监测对Ph(-) B-ALL的预后判断有重要意义。." @default.
• W3024885593 created "2020-05-21" @default.
• W3024885593 creator A5001025623 @default.
• W3024885593 creator A5005196775 @default.
• W3024885593 creator A5010320081 @default.
• W3024885593 creator A5022850060 @default.
• W3024885593 creator A5028033669 @default.
• W3024885593 creator A5029167025 @default.
• W3024885593 creator A5031656737 @default.
• W3024885593 creator A5032722532 @default.
• W3024885593 creator A5035317876 @default.
• W3024885593 creator A5048554505 @default.
• W3024885593 creator A5057527233 @default.
• W3024885593 creator A5063401098 @default.
• W3024885593 creator A5063463267 @default.
• W3024885593 creator A5075997639 @default.
• W3024885593 creator A5084238922 @default.
• W3024885593 creator A5084909175 @default.
• W3024885593 creator A5086214965 @default.
• W3024885593 date "2018-09-14" @default.
• W3024885593 modified "2023-09-27" @default.
• W3024885593 title "[Clinical significance of minimal residual disease in patients with Ph-negative precursor B-acute lymphoblastic leukemia]." @default.
• W3024885593 cites W1967348190 @default.
• W3024885593 cites W1977921909 @default.
• W3024885593 cites W1998660089 @default.
• W3024885593 cites W2004437400 @default.
• W3024885593 cites W2007234423 @default.
• W3024885593 cites W2049000194 @default.
• W3024885593 cites W2050152294 @default.
• W3024885593 cites W2052739233 @default.
• W3024885593 cites W2081127271 @default.
• W3024885593 cites W2082669518 @default.
• W3024885593 cites W2086210609 @default.
• W3024885593 cites W2109388187 @default.
• W3024885593 cites W2125233997 @default.
• W3024885593 cites W2740355617 @default.
• W3024885593 cites W4292490709 @default.
• W3024885593 doi "https://doi.org/10.3760/cma.j.issn.0253-2727.2018.09.004" @default.
• W3024885593 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7342254" @default.
• W3024885593 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30369181" @default.
• W3024885593 hasPublicationYear "2018" @default.
• W3024885593 type Work @default.
• W3024885593 sameAs 3024885593 @default.
• W3024885593 citedByCount "1" @default.
• W3024885593 countsByYear W30248855932019 @default.
• W3024885593 crossrefType "journal-article" @default.
• W3024885593 hasAuthorship W3024885593A5001025623 @default.
• W3024885593 hasAuthorship W3024885593A5005196775 @default.
• W3024885593 hasAuthorship W3024885593A5010320081 @default.
• W3024885593 hasAuthorship W3024885593A5022850060 @default.
• W3024885593 hasAuthorship W3024885593A5028033669 @default.
• W3024885593 hasAuthorship W3024885593A5029167025 @default.
• W3024885593 hasAuthorship W3024885593A5031656737 @default.
• W3024885593 hasAuthorship W3024885593A5032722532 @default.
• W3024885593 hasAuthorship W3024885593A5035317876 @default.
• W3024885593 hasAuthorship W3024885593A5048554505 @default.
• W3024885593 hasAuthorship W3024885593A5057527233 @default.
• W3024885593 hasAuthorship W3024885593A5063401098 @default.
• W3024885593 hasAuthorship W3024885593A5063463267 @default.
• W3024885593 hasAuthorship W3024885593A5075997639 @default.
• W3024885593 hasAuthorship W3024885593A5084238922 @default.
• W3024885593 hasAuthorship W3024885593A5084909175 @default.
• W3024885593 hasAuthorship W3024885593A5086214965 @default.
• W3024885593 hasConcept C126322002 @default.
• W3024885593 hasConcept C143998085 @default.
• W3024885593 hasConcept C2776694085 @default.
• W3024885593 hasConcept C2778461978 @default.
• W3024885593 hasConcept C2779823535 @default.
• W3024885593 hasConcept C2909962599 @default.
• W3024885593 hasConcept C3018657049 @default.
• W3024885593 hasConcept C63363279 @default.
• W3024885593 hasConcept C71924100 @default.
• W3024885593 hasConcept C90924648 @default.
• W3024885593 hasConceptScore W3024885593C126322002 @default.
• W3024885593 hasConceptScore W3024885593C143998085 @default.
• W3024885593 hasConceptScore W3024885593C2776694085 @default.
• W3024885593 hasConceptScore W3024885593C2778461978 @default.
• W3024885593 hasConceptScore W3024885593C2779823535 @default.
• W3024885593 hasConceptScore W3024885593C2909962599 @default.
• W3024885593 hasConceptScore W3024885593C3018657049 @default.
• W3024885593 hasConceptScore W3024885593C63363279 @default.
• W3024885593 hasConceptScore W3024885593C71924100 @default.
• W3024885593 hasConceptScore W3024885593C90924648 @default.
• W3024885593 hasIssue "9" @default.
• W3024885593 hasLocation W30248855931 @default.
• W3024885593 hasOpenAccess W3024885593 @default.
• W3024885593 hasPrimaryLocation W30248855931 @default.
• W3024885593 hasRelatedWork W2007230786 @default.
• W3024885593 hasRelatedWork W2014302553 @default.
• W3024885593 hasRelatedWork W2022129113 @default.
• W3024885593 hasRelatedWork W22609921 @default.
• W3024885593 hasRelatedWork W2364242575 @default.
• W3024885593 hasRelatedWork W2380499001 @default.
• W3024885593 hasRelatedWork W2392436082 @default.
• W3024885593 hasRelatedWork W2393726132 @default.
• W3024885593 hasRelatedWork W2418294496 @default.
• W3024885593 hasRelatedWork W4247941550 @default.
• W3024885593 hasVolume "39" @default.

• next